Effect of Denosumab in Erosion Healing in RA

Effect of RANKL Inhibition on Healing of Bone Erosion in Rheumatoid Arthritis Using HR-pQCT

To evaluate the effects of denosumab on erosion healing and change in physical function in RA patients.

This is a randomized, double-blind, placebo-controlled study, which aimed to evaluate the effects of denosumab on erosion healing and change in physical function in rheumatoid arthritis (RA) patients in low-disease activity or remission receiving synthetic DMARDs (sDMARDs) treatment using High-resolution peripheral quantitative CT (HR-pQCT).

Inclusion Criteria:

• ≥18 years old
• DAS28 ≤5.1
• without severe deformity in MCP joints which would influence the longitudinal assessment of HR-pQCT

Exclusion Criteria:

• RA functional status class IV (limited in ability to perform usual self-care, vocational, and avocational activities)
• treatment with any biologic DMARDs for RA treatment within 8 weeks before randomisation
• pregnancy or premenopausal women planning pregnancy
• previous use of denosumab, zoledronic acid or teriparatide
• Hyperparathyroidism
• contraindications to denosumab
• Bisphosphonate, biologic DMARDs and the use of oral glucocorticoid >10 mg/day (prednisolone equivalent)